Novartis loses patent litigation related to multiple sclerosis drug Gilenya
A modified panel of CAFC reversed the decision upholding the validity of the Gilenya dosing regimen patent granted…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Jun 22
A modified panel of CAFC reversed the decision upholding the validity of the Gilenya dosing regimen patent granted…
21 Jun 22
The NMPA approval is based on the interim analysis of the Phase 3 ORIENT-15 clinical trial, in which…
21 Jun 22
Pfizer and Valneva have updated the terms of their existing collaboration and license agreement for the development of…
17 Jun 22
Exelixis is enabled to expand its biotherapeutics pipeline by selecting antibody candidates against targets identified using BioInvent’s immuno-oncology…
17 Jun 22
In the study, crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation…
16 Jun 22
Under the collaboration, the Abu Dhabi health regulator and Sanofi will develop data generation and population research projects…
16 Jun 22
The rolling review is initially based on chemistry, manufacturing, and controls (CMC) data, which the vaccine manufacturers shared…
15 Jun 22
With the collaboration with Agilent, Merck will extend its real-time monitoring and automated process control of critical process…
15 Jun 22
The US antitrust watchdog has issued a letter to the company that said the FTC was investigating whether…
14 Jun 22
Albrioza, also known as AMX0035, is an oral fixed-dose combination therapy that works to reduce neuronal cell death…